¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-19
±³À°ÀÏÀÚ : 2019-10-19
±³À°Àå¼Ò : ¿öÄ¿Èú È£ÅÚ Art ¿Ü  
±³À°ÁÖÁ¦ : KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ)
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  
À̸ÞÀÏ : herz8@circulation.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í »çÀüµî·Ï: ±³¼ö ¹× °³¿øÀÇ-100000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ-70000ÇöÀåµî·Ï: ±³¼ö ¹× °³¿øÀÇ-120000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ-90000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-19 Art 08:40~09:00 Role of Strain Echocardiography  Á¶±¸¿µ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-19 Art 09:00~09:20 Role CMR  ÃÖ¿¬Çö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-19 Art 09:20~09:40 Role of Cardiac CT with FFR  ±è¿µÇÐ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-19 Art 09:40~10:00 Role of Nuclear Imaing  °­¿øÁØ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 10-19 Art 10:00~10:10 Discussion  () 
È޽Ġ10-19  10:10~10:20 Break  () 
±³À°½Ã°£ 10-19 Calla 10:20~10:40 Role of Vascular Smooth Cell in the Inflammaging of the Artery  Sung Ha Park(Yonsei Univ. Korea) 
±³À°½Ã°£ 10-19 Calla 10:40~11:00 Molecular Imaging for Vascular Inflammation and Atherosclerosis  Jonathan R. Lindner(Oregon Health & Science Univ. USA) 
±³À°½Ã°£ 10-19 Calla 11:00~11:20 Vascular Calcification: Pathogenesis and Clinical Implications  Hae-Young Lee(Seoul National Univ. Korea) 
±³À°½Ã°£ 10-19 Calla 11:20~11:40 Assessment of Capillary Function in Diabetes and Metabolic Syndrome  Jonathan R. Lindner(Oregon Health & Science Univ. USA) 
Åä·Ð 10-19 Calla 11:40~11:50 Discussion  () 
È޽Ġ10-19  11:50~12:00 Break  () 
±³À°½Ã°£ 10-19 Cosmos 12:00~12:20 Optimal Anti-Hypertensives in CardioMetabolic Diseases with Hypertension  ¹Ú»ó¹Î(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-19 Cosmos 12:20~12:40 New Paradigm of Combination Therapy for Uncontrolled Hypertensive Patients  ÀÌÁÖÈñ(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 10-19 Abstract/Case zone & Moderated Poster zone 12:40~14:00 Case Presentation & Moderated Poster  ´Ù°­»ç(´Ù¼Ò¼Ó) 
±³À°½Ã°£ 10-19 Walker 2 14:00~14:20 Best Coronary Revascularization Strategy in Diabetic Patients  ¹Ú´ö¿ì(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-19 Walker 2 14:20~14:40 Secondary Prevention for Coronary Artery Disease in Diabetic Patients  È«¼øÁØ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10-19 Walker 2 14:40~15:00 From Evidence to Practice: SGLT2 Inhibitors for CV Risk Reduction in Diabetes  ÀÓ¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-19 Walker 2 15:00~15:20 From Evidence to Practice: GLP-1 analogues for CV Risk Reduction in Diabetes  ±èº´ÁØ(°¡ÃµÀÇ´ë) 
Åä·Ð 10-19 Walker 2 15:20~15:30 Discussion  () 
È޽Ġ10-19  15:30~15:40 Break  () 
±³À°½Ã°£ 10-19 Theatre 15:40~15:55 Antithrombotic Therapy in Patients with AF Undergoing PCI: Dual or Triple Therapy?  ¹Ú±ÙÈ£(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 10-19 Theatre 15:55~16:10 Antithrombotic Strategy in AF with Stable CAD and PAD  Á¤¿µÈÆ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 10-19 Theatre 16:10~16:25 Antithrombotic Therapy in Korean Patients with AF and CAD: Where Are We Now?  À̼ҷÉ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-19 Theatre 16:25~16:40 Periprocedual Management in AF Patients with NOACs: PCI and RFCA  À¯ÈñÅÂ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-19 Theatre 16:40~16:55 Left Atrial Appendage Occlusion in AF Patient with CAD: Which Patients Would Undergo?  ÀÓÈ«ÀÇ(ÇѸ²ÀÇ´ë) 
Åä·Ð 10-19 Theatre 16:55~17:10 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼­¿ï¼º¸ðº´¿ø ´ëÇÑ¿Ü°úÀ§³»½Ã°æ¿¬±¸È¸ 2019³â ÇϹݱ⠼ú±â ¿öÅ©¼ó ¹× ¿¬¼ö°­Á : 2019-10-19
´ÙÀ½±Û ¼­¿ï¼º¸ðº´¿ø 2019 ´ëÇѼҾÆû¼Ò³â°úÀÇ»çȸ ¼­¿ïÁöȸ ¿öÅ©¼¥ : 2019-10-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20910 ¼­¿ï 2024³â Á¦14ȸ °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú ¿¬¼ö°­Á : 2024-07-07 0 4 2024-05-28
20909 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¤Çü¿Ü°ú 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-07-07 0 8 2024-05-28
20908 ¼­¿ï Á¦19Â÷ ´ëÇѸðÀ¯¼öÀ¯ÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-07 0 9 2024-05-28
20907 °æ±â Á¦2Â÷ ´ëÇѽŰæ¹æ»ç¼±¼ö¼úÇÐȸ Á¤±âÇмú´ëȸ : 2024-07-06 0 8 2024-05-28
20906 °æ±â Á¦ 5ȸ ¿À»ê½ÃÀÇ»çȸ Çмú´ëȸ : 2024-07-06 0 5 2024-05-28
20905 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦3ȸ ¾Æ»êµÎ°æºÎ Æ÷·³ : 2024-07-06 0 8 2024-05-28
20904 ¼­¿ï 2024³â Á¦2ȸ °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼øȯ±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 9 2024-05-28
20903 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day3) : 2024-07-06 0 9 2024-05-28
20902 ¼­¿ï ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ 2024³â ÇÏ°è NeurocrItical Care Essence (NICE) ¾ÆÄ«µ¥¹Ì : 2024-07-06 0 5 2024-05-28
20901 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦10ȸ ºÎ½Å¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 2 2024-05-28
20900 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 4 2024-05-28
20899 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 8 2024-05-28
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 3 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 4 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 5 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷